Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
shRNA-modified CD34+ Cells in HIV
NCT03517631Phase 1Unknown
- Start
- Feb 2018
- Primary completion
- Dec 2020
- Modality
- Gene Editing, Viral-delivered RNAi, Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of shRNA-modified CD34+ cells in human immunodeficiency virus infection (HIV) (3 arms). Primary endpoint: Adverse side effects at 18 months. Status: unknown.
02
Drugs
shRNA-modified CD34+ cells
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03517631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03517631.